Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart

Archives of Internal Medicine

Volumn 164, Issue 16, 2004, Pages 1737-1748

  Lim, Hoong Sern ^a   MacFadyen, Robert J ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; RAMIPRIL; RENIN; ROSIGLITAZONE; RUBOXISTAURIN; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG RESPONSE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MICROVASCULATURE; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTECTION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

CLINICAL TRIALS; DIABETES MELLITUS; HEART DISEASES; HUMANS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 4544278755     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.16.1737     Document Type: Review

References (150)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care. 1998; 21:1414-1431.
2. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care. 1999; 22:1266-1272.
3. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979;59:8-13.
4. Stamler J, Vaccaro O, Neaton J. Diabetes, other risk factors, and the 12-year cardiovascular mortality for men in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
5. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without myocardial infarction. N Engl J Med. 1998;339:229-234.
6. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS Registry. Circulation. 2000;102:1014-1019.
7. Cho E, Rimm EB, Stampfer MJ, et al. The impact of diabetes and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002; 40:954-960.
8. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch Intern Med. 2001;161:1717-1723.
9. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
10. Zuraw B. Bradykinin in protection against left-ventricular hypertrophy. Lancet. 2001;358:1116-1118.
11. Dell'Italia LJ, Oparil S. Bradykinin in the heart [editorial]. Circulation. 1999;100:2305-2307.
12. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937-942.
13. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
14. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
15. Givertz MM. Manipulation of the renin-angiotensin system. Circulation. 2001;104:14-18.
16. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-645.
17. Francis GS. ACE inhibition in cardiovascular disease [editorial]. N Engl J Med. 2000;342:201-202.
18. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
19. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123-1132.
20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
21. Laursen JB, Rajagopalan S, Galis ZS, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593.
22. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH oxidase-mediated superoxide production in the early stages of atherosclerosis. Circulation. 1999;99:2027-2033.
23. Munzel T, Keaney JF. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation. 2001; 104:1571-1574.
24. Miller JA, Floras JS, Zinman B, et al. Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci. 1996;90:189-195.
25. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol. 1999;10:1778-1785.
26. Osei SY, Price DA, Laffel LMB, et al. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension. 2000;36:122-126.
27. Leri A, Claudio PP, Wang XX, et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin angiotensin system and decreases the Bel-2 to Bax protein ratio in the cell. J Clin Invest. 1998;101:1326-1342.
28. Leri A, Fiordaliso F, Setoguchi M, et al. Inhibition of p53 function prevents renin angiotensin system activation and stretch-mediated myocyte apoptosis. Am J Pathol. 2000;157:843-857.
29. Fiordaliso F, Leri A, Cesselli D, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001; 50:2363-2375.
30. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33: 613-621.
31. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet. 2000;355: 253-259.
32. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001; 286:1882-1885.
33. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
34. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
35. Bloomgarden ZT. European Association for the Study of Diabetes annual meeting 1999-complications of diabetes. Diabetes Care. 2000; 23:1423-1428.
36. Malmberg K, Ryden L, Efendic SI et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study). J Am Coll Cardiol. 1995;26:57-65.
37. Woodfield S, Lundergan R, Reiner J, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy in acute myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol. 1996;28:1661-1669.
38. Fava S, Azzopardi J, Muscat HA, et al. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care. 1993;16: 1615-1618.
39. GUSTO-1 Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation. 1995;91:1659-1668.
40. Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care. 1988;11:351-358.
41. Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in diabetic patients. Am Heart J. 1984;108:31-37.
42. Aronson O, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med. 1997;126:296-306.
43. Gwilt DJ, Petri M, Lewis PW, et al. Myocardial infarct size and mortality in diabetic patients. Br Heart J. 1985;54:466-472.
44. MILIS Study Group. The effects of diabetes mellitus on prognosis and serial left ventricular function after myocardial infarction. J Am Coll Cardiol. 1989;14:49-57.
45. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension and cardiovascular disease. Hypertension 2001;37:1053-1059.
46. Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. J Hum Hypertens. 1999;13:S3-S8.
47. Reaven GM. Intensive blood pressure/glucose control in type 2 diabetes: why is it so difficult to decrease coronary heart disease? J Hum Hypertens. 1999;13:S19-S23.
48. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25:S71-S73.
49. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
50. HOT study group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
51. Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
52. Bakris GL, Williams M, Dworkin L, et al; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes. Am J Kidney Dis. 2000;36:646-661.
53. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38:E28-E32.
54. Lip GYH, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease: a complex syndrome or a hypertensive "cardiomyopathy"? Eur Heart J. 2000;21:1653-1665.
55. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
56. Motz W, Strauer BE. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension. 1996;27:1031-1038.
57. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists. J Am Coll Cardiol. 2002;40:703-709.
58. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258-265.
59. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
60. Grines CL, Topol EJ, Califf RM, et al. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. Circulation. 1989;80:245-253.
61. Iwasaka T, Takahashi N, Nakamura S, et al. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care. 1992;15:1522-1526.
62. Balletshofer BM, Rittig K, Enderle MO, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 2000;101:1780-1784.
63. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36-52.
64. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44:129-146.
65. Miyata S, Monnier VM. Immunohistochemical detection of AGEs in diabetic tissues using monoclonal antibody to pyrraline. J Clin Invest. 1992; 89:1102-1112.
66. Palinski W, Koschinsky T, Butler S, et al. Immunological evidence for the presence of AGEs in atherosclerotic lesions of euglycaemic rabbits. Arterioscler Thromb Vasc Biol. 1995;15:571-582.
67. Berry C, Hamilton CA, Brosnan J, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000;101:2206-2212.
68. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996; 94:2756-2767.
69. van Harsdorf R, Li PF, Dietz R. Signalling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999;99: 2934-2941.
70. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
71. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347: 305-313.
72. Messerli FH, Sungaard-Riise K, Reisin E, et al. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med. 1983;74:808-812.
73. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med. 2001;79:21-29.
74. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35: 1270-1277.
75. Price DA, Lansang MC, Osei SY, et al. Type 2 diabetes; obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med. 2002;19:858-862.
76. Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab. 1986;15:855-888.
77. Stevens MS, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation. 1998;98:961-968.
78. Zola B, Kahn JK, Juni JE, et al. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease. J Clin Endocrinol Metab. 1986;63:208-214.
79. O'Brien OA, McFadden JP, Corral RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med. 1991;290: 495-502.
80. Rathman W, Ziegler D, Jahnke M, et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med. 1993;10:820-824.
81. Monteagudo PT, Moises VA, Kohlmann O, et al. Influence of autonomic neuropathy upon left ventricular dysfunction in insulin-dependent diabetic patients. Clin Cardiol. 2000;23:371-375.
82. Scognamiglio R, Avogaro A, Casara O, et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998;31:404-412.
83. Toyry JP, Niskanen LK, Mantysaari MJ, et al. Occurrence, predictors and clinical significance of autonomic neuropathy in NIDDM. Diabetes. 1996; 45:308-315.
84. Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med. 1980;92:308-311.
85. Timmis AD. Diabetic heart disease: clinical considerations. Heart. 2001;85:463-469.
86. Airaksinen KEJ. Silent coronary artery disease in diabetes: a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia. 2001;44:259-266.
87. Hamby RI, Zoneraich S, Sherman S. Diabetic cardiomyopathy. JAMA. 1974;29:1749-1754.
88. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol. 1974;34:29-34.
89. Fein FS. Diabetic cardiomyopathy. Diabetes Care. 1990;3:1169-1179.
90. Hardin NJ. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis. 1996;7:99-108.
91. Regan TJ, Ettinger PO, Kahn MI, et al. Altered myocardial function and metabolism in chronic diabetes mellitus without ischemia in dogs. Circ Res. 1974;35:222-237.
92. Jackson CV, McGrath GM, Tahiliani AG, et al. A functional and ultrastructural analysis of experimental diabetic rat myocardium. Diabetes. 1985;34: 876-883.
93. Ren J, Bode AM. Altered cardiac excitation-contraction coupling in ventricular myocytes from spontaneously diabetic BB rats. Am J Physiol Heart Circ Physiol. 2000;279:H238-H244.
94. Kawano K, Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1993;41:1422-1428.
95. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101:899-907.
96. Shapiro LM, Howat AP, Calter MM. Left ventricular function in diabetes mellitus, I: methodology and prevalence and spectrum of abnormalities. Br Heart J. 1981;45:122-128.
97. Shapiro LM, Leatherdale BA, Mackinnon J, et al. Left ventricular function in diabetes mellitus, II: relation between clinical features and left ventricular function. Br Heart J. 1981;45:129-132.
98. Shapiro LM. Echocardiographic features of impaired ventricular function in diabetes mellitus. Br Heart J. 1982;47:439-444.
99. Seneviratne BIB. Diabetic cardiomyopathy: the preclinical phase. BMJ. 1977;1:1444-1446.
100. Posner I, Ilya R, Wanderman K, et al. Systolic time intervals in diabetes. Diabetologia. 1983; 24:249-252.
101. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68:85-89.
102. Borow KM, Jaspan JB, William KA, et al. Myocardial mechanics in young adult patients with diabetes mellitus. J Am Coll Cardiol. 1990;15: 1508-1517.
103. Gustafsson I, Hildebrandt P. Early failure of the diabetic heart [editorial]. Diabetes Care. 2001; 24:3-4.
104. Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart. 2001;85:247-248.
105. Bell DS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18:708-714.
106. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? Diabetes Care. 1994;17:633-639.
107. Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Diabetes Care. 2001;1:5-10.
108. Hirai J, Ueda K, Takegoshi T, et al. Effects of metabolic control on ventricular function in type 2 diabetic patients. Intern Med. 1992;31:725-730.
109. Uusitupa M, Siitonen O, Aro A, et al. Effect of correction of hyperglycemia on left ventricular function in non-insulin-dependent (type 2) diabetics. Acta Med Scand. 1983;213:363-368.
110. Dhalla WS, Liu X, Panagia V, et al. Subcellular remodelling and heart dysfunction in chronic diabetes. Cardiovasc Res. 1998;40:239-247.
111. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
112. Wakasaki H, Koya D, Schuen FJ, et al. Targeted overexpression of protein kinase C isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci U S A. 1997;94:9320-9325.
113. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2002;25:S85-S89.
114. Opie LH, Parving HH. Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? Circulation. 2002;106:643-645.
115. Ruilope LM, van Veldhuisen DJ, Ritz E, et al. Renal function; the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001;38:1782-1787.
116. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
117. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
118. Kocks MJ, de Zeeuw D, Navis GJ. Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease. Curr Opin Nephrol Hypertens. 2002;11:135-140.
119. Wright JT, Bakris GL, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA. 2002;288:2421-2431.
120. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibitor on diabetic nephropathy. N Engl J Med. 1993;329: 1456-1462.
121. EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
122. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
123. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
124. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effects of the angiotensin receptor blocker irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
125. Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
126. MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation. 2002;106:672-678.
127. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
128. Murase K, Odaka H, Suzuki N, et al. Pioglitazone time-dependently reduces tumour necrosis factor α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia. 1998;41:257-264.
129. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator activated receptor-γ activators. Circulation. 2000;101:235-238.
130. Neve BP, Corseaux D, Chinetti G, et al. PPAR-α agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103:207-212.
131. Tham DM, Martin-McNulty B, Wang Y, et al. Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol Genomics. 2002;11:21-30.
132. MacFadyen RJ, Lee AFC, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82:57-61.
133. Jorde UP, Vittorio T, Katz SD, et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 2002; 106:1055-1057.
134. CONSENSUS Trial Study Group, Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
135. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe congestive heart failure. N Engl J Med. 1999;341:709-717.
136. Rincon-Choles H, Kasinath BS, Gorin Y, et al. Angiotensin II and growth (actors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl. 2002;82:8-11.
137. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
138. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
139. SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-691.
140. AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
141. SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
142. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752-760.
143. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
144. Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
145. Cappuccio FP, Cook DG, Atkinson RW, et al. Prevalence, detection and management of cardiovascular risk factors in different ethnic groups in south London. Heart. 1997;78:555-563.
146. Balarajan R. Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ. 1991;302:560-564.
147. ALLHAT Officers and Coordinators; ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288: 2981-2997.
148. Douglas JG, Bakris G, Epstein M, et al; Hypertension in African Americans Working Group. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525-541.
149. Epstein AE, Bigger JT, Wyse DG, et al. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. J Am Coll Cardiol. 1991;18:14-19.
150. Minnesota Heart Survey Investigators. Recent trends in acute coronary heart disease. N Engl J Med. 1996;334:884-890.